Acurion Secures 4.3 Million Dollars to Accelerate AI-Powered Precision Oncology Platform

San Diego based Acurion recently announced the closing of a 4.3 million dollar seed financing round to advance its proprietary OncoGaze platform. The funding was oversubscribed, surpassing its initial 4 million dollar target, and was led by TK Partners with participation from Mesa Verde Venture Partners. This capital will support clinical validation, regulatory preparation, and the commercialization of AI tools designed to detect cancer biomarkers instantly.

The OncoGaze platform represents a major technological leap by using deep learning to analyze routine pathology slides prepared during standard clinical care. Unlike traditional genomic testing which can take weeks and requires additional tissue samples, this software identifies actionable insights in seconds. This approach aims to make precision medicine more accessible to patients in various clinical settings by removing the need for specialized molecular infrastructure.

CEO Rick Fultz stated that the future of oncology depends on making biomarker detection instantly actionable in real world environments. The investment helps the company move closer to a meaningful impact for cancer patients who currently face life-threatening delays in testing. By integrating directly into existing workflows, the technology provides community oncologists with the same rapid diagnostic tools previously limited to elite research institutions.

Acurion's scientific foundation is built upon the work of co-founder Ludmil Alexandrov, a professor at UC San Diego known for his research on mutational signatures. The platform has already demonstrated a high degree of efficacy in detecting Homologous Recombination Deficiency in several cancer types. Studies indicate that it can identify significantly more positive patients than standard molecular assays, potentially expanding the pool of candidates for targeted therapy. Beyond technical validation, the company has secured strategic partnerships, including an agreement with the Pancreatic Cancer Action Network. This collaboration provides access to large datasets that further refine the AI models. Such data moats are critical for maintaining a competitive edge and ensuring high accuracy across diverse patient populations in the rapidly evolving digital pathology sector. The company is now focused on executing key regulatory milestones to bring OncoGaze into the hands of more physicians globally. As precision therapies continue to expand, the demand for rapid, scalable diagnostic tools is expected to grow. Acurion plans to announce further clinical collaborations and regulatory progress in the coming months as they scale their operations.